Baxter Healthcare

Activities: Manufacturing

Trending Articles

  1. The US FDA bans colour additive Red No. 3 from use in oral solid dosage forms Ingestible drug manufacturers will have until January 18, 2028 to reformulate their products, as Red No. 3 has been linked to cancer in male rats
  2. Touchlight becomes the first synthetic DNA API manufacturer to receive GMP certification The CDMO's Hampton, UK facility has received GMP certification to produce investigational APIs and critical starting materials for DNA vaccines and non-viral gene therapies
  3. Navin Molecular constructs a new R&D facility in Dewas, India The laboratory will enhance the CDMO's small molecule laboratory- and kilo-scale process development capabilities, as well as its analytical development and testing capacity
  4. At MD&M West, TekniPlex Healthcare to emphasise turnkey capabilities for class III implantables and delivery systems Concept-to-commercialisation services include precision, tight-tolerance metalworking expertise and injection moulding solutions; company also will display bio-based PVC...
  5. TheHill and IMed Consultancy team up for digital health start-ups TheHill enlists IMed Consultancy for regulatory advice to start-ups in flagship NHS Market Access Accelerator Programme

Upcoming event

Pharmapack

22 – 23 January 2025 | Exhibition | Paris, France See all

Related Content

Drug Delivery

US FDA approves cardiovascular medicine from Baxter

The premixed format of eptifibatide to treat acute coronary syndrome is the first of its kind available in a flexible container
You need to be a subscriber to read this article.
Click here to find out more.
Training & Education

Updating the Book

Modern methods for modern times
Regulatory

Indian pricing authority to address overcharging by pharma companies

NPPA has decided to chase drug majors for defaulting on penalties that have been imposed for overcharging consumers for medicines
Regulatory

Baxter recalls multivitamin powder after glass particles are found

Preliminary investigations point to an isolated event, says MHRA
Containment

Extract delivers 'remarkable service' to an international healthcare company

When any request is received, the After Market department makes every effort to resolve site issues within the shortest possible time frame
Manufacturing

Update on SafeBridge potent compound safety certification programme

The programme provides drug innovators with an independent assessment of a manufacturing company’s ability to safely produce potent APIs and drug products
Regulatory

Myelofibrosis – pacritinib

Myelofibrosis is a chronic, serious and life-threatening disorder of the bone marrow with a median survival of six years - and much less for very high risk patients
Subscribe now